Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M709941200 on January 15, 2008

J. Biol. Chem., Vol. 283, Issue 12, 7523-7530, March 21, 2008
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/12/7523    most recent
M709941200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, Y.
Right arrow Articles by Harrison, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, Y.
Right arrow Articles by Harrison, R. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

cAMP-dependent Protein Kinase Phosphorylation Produces Interdomain Movement in SUR2B Leading to Activation of the Vascular KATP Channel*Formula

Yun Shi{ddagger}1, Xianfeng Chen{ddagger}§1, Zhongying Wu{ddagger}, Weiwei Shi{ddagger}, Yang Yang{ddagger}, Ningren Cui{ddagger}, Chun Jiang{ddagger}2, and Robert W. Harrison§3

From the Departments of {ddagger}Biology and §Computer Science, Georgia State University, Atlanta, Georgia 30302-4010

Received for publication, December 5, 2007


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Vascular ATP-sensitive K+ channels are activated by multiple vasodilating hormones and neurotransmitters via PKA. A critical PKA phosphorylation site (Ser-1387) is found in the second nucleotide-binding domain (NBD2) of the SUR2B subunit. To understand how phosphorylation at Ser-1387 leads to changes in channel activity, we modeled the SUR2B using a newly crystallized ABC protein SAV1866. The model showed that Ser-1387 was located on the interface of NBD2 with TMD1 and physically interacted with Tyr-506 in TMD1. A positively charged residue (Arg-1462) in NBD2 was revealed in the close vicinity of Ser-1387. Mutation of either of these three residues abolished PKA-dependent channel activation. Molecular dynamics simulations suggested that Ser-1387, Tyr-506, and Arg-1462 formed a compact triad upon Ser-1387 phosphorylation, leading to reshaping of the NBD2 interface and movements of NBD2 and TMD1. Restriction of the interdomain movements by engineering a disulfide bond between TMD1 and NBD2 prevented the channel activation in a redox-dependent manner. Thus, a channel-gating mechanism is suggested through enhancing the NBD-TMD coupling efficiency following Ser-1387 phosphorylation, which is shared by multiple vasodilators.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
ATP-sensitive K+ (KATP)4 channels play an important role in vascular tone regulation (1–3). The KATP channels are expressed in vascular smooth muscles (VSMs) and activated by several vasodilating hormones and neurotransmitters through the Gs-cAMP-PKA signaling system (1, 4, 5). The channel activation leads to hyperpolarization of VSM cells, decrease in voltage-dependent Ca2+ channel activity, and relaxation of resistant arteries (6).

KATP channels consist of 4 pore-forming Kir6x and 4 regulatory SURx subunits (7). The Kir6.1/SUR2B channel is the major isoform of KATP channels in VSMs (8–11). The channel does not open spontaneously at rest. Several groups of channel openers activate the channel, including pharmacological KATP channel openers (KCOs, e.g. pinacidil and nicorandil) (12), metabolites (MgADP, acidosis) (13, 14), and hormonal vasodilators and neurotransmitters (calcitonin gene-related peptide, epoxyeicosatrienoic acids, β-adrenergic receptor agonists, and vasoactive intestinal polypeptide) (5, 15–17). KCOs and Mg2+ nucleotides activate the KATP channels via binding to the SUR subunits (12, 18). The hormonal vasodilators activate the vascular KATP channel through direct phosphorylation of the channel protein by PKA (4, 5). Our resent study has shown that Ser-1387 is a key phosphorylation site (5).

It is unclear how phosphorylation at the Ser-1387 residue in SUR2B leads to channel activation. SURs belong to the ABC transporter protein family (19). All ABC proteins have an essential domain assembly, i.e. two transmembrane domains (TMD1 and TMD2) and two intracellular nucleotide-binding domains (NBD1 and NBD2). In addition, SURs have another transmembrane domain containing 5 helical segments termed TMD0 (Fig. 1A). The cytosolic NBDs of several ABC proteins have been crystallized (20–23). They all show similar sandwich-like structures with nucleotides clamped between two NBDs. Several NBD motifs, such as Walker A (13, 24), Walker B (25–27), and signature sequences (28) are known to be important for nucleotide binding. How the channel is activated with nucleotide binding, however, is still not fully understood. Experimental evidence suggests that TMDs play a major role in interacting with Kir6 subunits (29). Such interaction has been observed in recombinant Kir6.2/SUR1 channels using electronic microscopy (30). Moreover, the TMD0 and ICL0 are involved in KATP gating by channel modulators and nucleotides (31, 32). Therefore, signals of NBDs must be coupled to TMDs to fulfill channel gating.

Several ABC proteins have been crystallized in full-length with TMDs (33–36). These include the recently crystallized SAV1866 that is a homologue of mammalian ABC proteins (36) and shows the highest sequence similarity to SUR2B. Using the SAV1866 crystal structure, we modeled the core of SUR2B (SUR2B_core) containing TMD1, TMD2, NBD1, and NBD2 with particular attention to conformational changes after Ser-1387 phosphorylation. Our combined studies of modeling, molecular dynamics simulations, functional assays, and mutational analysis showed that Ser-1387 was located on the interface between TMDs and NBDs where it formed a triad with Tyr-506 and Arg-1462 after phosphorylation. The triad appeared to strengthen the interaction of NBD2 with TMD1, and enhanced the necessary force coupling between the two protein domains for channel gating. The model also indicates that the NBD-TMD interaction in SURs can be well represented by the SAV1866 structure.


Figure 1
View larger version (69K):
[in this window]
[in a new window]

  		FIGURE 1.
SUR2B_core model. A, skeletal representation of the KATP channel. Kir6.1 (left) has two transmembrane helices (TMHs) with both N and C termini located in the cytosol. SUR2B has 17 TMHs, forming three transmembrane domains (TMD0, TMD1, and TMD2) in a 5-6-6 pattern. The N terminus is located extracellularly and the C terminus intracellularly. The NBD1 is located between TMD1 and TMD2, and NBD2 lies in the C terminus. The ICLs between TMHs are indicated. The SUR2B_core includes sequences from TMD1 to the C terminus. The region between residues 286 (arrow a1) and 914 (a2) was designated TM-NBD1. The residues between 976 (a3) and 1546 (C terminus) were designated TM-NBD2. TM-NBD1 and TM-NBD2 were aligned to SAV1866 and used to generate the SUR2B_core model. A few residues between a2 and a3 were excluded in the SUR2B_core model as they do not have homology with SAV1866. B, overall structure of SUR2B_core. TMD1 (residues 286–617, green) was linked with NBD1 (residues 666–913, blue) with 38 residues (loop in gray). TMD2 (residues 976–1289, red) was linked with NBD2 (residues 1310–1546, purple) with 20 residues. The linker regions between TMD1 and NBD1, TMD2 and NBD2 are longer than the corresponding regions in SAV1866, and thus they were looped beside the NBD domains (gray). The first nucleotide-binding pocket (formed by Walker A in NBD1 and the signature sequence in NBD2) was modeled with ATP (yellow). The second nucleotide-binding pocket (formed by Walker A in NBD2 and the signature sequence in NBD1) was modeled with ADP. C, interaction of the intracellular linkers with NBDs. ICL1 and ICL3 interacted with both NBD1 and NBD2 across the nucleotide-binding regions (yellow). ICL2 was inserted into a groove formed by the NBD2 surface, and ICL4 inserted into NBD1. D, details of the interaction between ICL2 and NBD2. NBD2 formed a big groove to host ICL2, in which β5 formed the bottom, Q-loop, {alpha}2, {alpha}3, {alpha}6, and a loop between {alpha}3 and {alpha}4 (named the C-loop because a cysteine residue, Cys-1408 was located in this segment) formed the walls. The phosphorylation site Ser-1387 was located in the β5-sheet and is shown in cyan.

 

   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Modeling of the SUR2B_core was based on the crystal structure of SAV1866 (PDB: 2HYD). The sequences of SAV1866 were aligned with both halves of the SUR2B_core (TM-NBD1 and TM-NBD2) using ClustalW. SAV1866 was 21.5% identical to the TM-NBD1 of SUR2B (46.5% similarities) and 21.3% to TM-NBD2 (47.8% similarities). The NBDs were highly conserved: 28.7% identical in NBD1 and 33.5% identical in NBD2. SAV1866_TMD were 16.0 and 12.8% identical to SUR2B_TMD1 and TMD2, respectively (~35% when amino acids with similar side chains were considered). Although the homology in amino acid sequences of TMDs is low, they can be aligned using the conserved topology within each TMD, i.e. six transmembrane helices (determined by hydrophobicity of the residues) in each domain with similar lengths. The sizes and positions of extracellular and intracellular linker regions were also comparable. There were only a few short gaps in the alignment (4 in TMD1 and 2 in TMD2, supplemental Fig. S1). The atomic coordinates of amino acids, nucleotides, and water molecules in the template (SAV1866) were transferred to the SUR2B_core model. The ADP molecule in the first nucleotide-binding pocket was replaced with ATP. The coordinates of ATP-binding Mg2+ and ADP-binding Mg2+ were obtained using the crystal structures of the ABC transporters HlyB (1XEF) and TAP1 (1JJ7), respectively. The linker regions between TMD1 and NBD1 (residues 618–665), and between TMD2 and NBD2 (residues 1290–1309) were modeled as surface loops in the structure. The linker between NBD1 and TMD2 (residues 914–975) was omitted from the model because of the lack of a template. Energy minimization was performed using 1000 steps of conjugate gradient optimization with the latest AMMP potential set (version tuna) (37). The model was viewed with PyMOL.


Figure 2
View larger version (46K):
[in this window]
[in a new window]

  		FIGURE 2.
Ser-1387 and surrounding sites in PKA phosphorylation. A, Ser-1387 was close to Tyr-506 and Arg-1462. The atom Og in the Ser-1387 side chain was 3.6 Å from atom Oh of Tyr-506, and ~8 Å from the positive charges of Arg-1462 (the middle of the two Nh atoms). B, forskolin (FSK, 10 µM) activated whole cell currents of Kir6.1/SUR2B, which were further activated by pinacidil (Pin, 10 µM) and inhibited by glibenclamide (Glib, 10 µM) (see supplemental Fig. S2 for details). C, channel with SUR2B_R1462A mutation failed to be activated by forskolin. D, SUR2B_Y506A mutant greatly diminished the channel activation by forskolin. E, summary of forskolin effects on wt and mutant Kir6.1/SUR2B channels. Note the Y506F mutant was not activated, and the R1462K mutant was activated by forskolin.

 
Molecular dynamics (MD) simulations were carried out to study the conformational change in the NBD-ICL2 interface. The SUR2B_core model contained many hydrophobic transmembrane segments that would require a very large molecular dynamics simulation including the lipid bilayer. Therefore, we constructed two models containing NBDs and an extended segment of ICL2 (residues 500–512) with and without a phosphate group linked to atom Og of Ser-1387. 7500 H2O were added to the model molecules to ensure an aqueous environment. Additional ions were added to neutralize the total charge of the protein. No screening dielectric term or bulk solvent correction was included. A constant dielectric of one was used. The amortized fast multipole algorithm in AMMP was used for the long-range terms in the non-bonded and electrostatic potentials so that no cutoff radius was employed (38). Simulations were performed with a constant NVT ensemble corresponding to a pressure of about 1 atm with the classical molecular mechanics MD program AMMP (37, 39). The temperature was set at 310 K. 1000 frames, one for each picosecond, were logged over a 1-ns MD run. The mode structures, which represent the most frequent position of each atom (37), and the root mean-squared deviation of C{alpha}s of each residue were calculated over 1000 frames.

Rat Kir6.1 (GenBankTM D42145 [GenBank] ) and mouse SUR2B (GenBankTM D86038 [GenBank] ) were used in the present study. The cDNAs were cloned in a eukaryotic expression vector pcNDA3.1. Site-specific mutations were generated using a site-directed mutagenesis kit based on the Pfu DNA polymerase (Stratagene, La Jolla, CA). The cDNAs were expressed in human embryonic kidney cells (HEK293) as previously described (5). Whole-cell patch clamp experiments were performed as detailed in a previous work (supplemental Fig. S2) (5).

Data are presented as means ± S.E. Differences in means were tested with the analysis of variance or Student's t test and accepted as significant if p ≤ 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Modeling of the SUR2B_Core—The dimerized SAV1866 was crystallized in the ADP-binding form (PDB: 2hyd). Based on this structure, we built a model of the SUR2B_core in which sequence identities to SAV1866 are 21.5% for the TM-NBD1 of SUR2B (46.5% similarities), and 21.3% for TM-NBD2 (47.8% similarities) (supplemental Fig. S1). NBD1 and NBD2 formed a tight heterodimer (Fig. 1C). There were two nucleotide-binding pockets on the interface between NBD1 and NBD2. A MgATP molecule was incorporated in the first nucleotide-binding pocket and a MgADP in the second pocket. Different nucleotides were used, because the first pocket was likely to be a high affinity ATP-binding site, and the second was likely to bind to MgADP (18, 40). In the SUR2B_core model, TMDs interact with NBDs via four short helices of intracellular linkers (ICLs, Fig. 1C). ICL1 and ICL3 interacted with the NBD surface across the nucleotide-binding regions. ICL2 from TMD1 inserted deeply into NBD2, while ICL4 from TMD2 inserted into NBD1 (Fig. 1C). NBD2 formed a spindle-like groove where a β-sheet (β5) formed the bottom while the Q-loop, C-loop, and several {alpha}-helices ({alpha}2, {alpha}3, and {alpha}6) lined the wall. Ser-1387 was located on β5 within the reach of ICL2 (<4 Å, Fig. 1D). The side-chain of an aromatic residue (Tyr-506) in ICL2 was inserted deeply into the NBD2 groove and was close to Ser-1387 in ~4 Å (Fig. 2A). Around Ser-1387 there was a positively charged residue (Arg-1462) in NBD2 at a distance that allows electrostatic interaction between them when Ser-1387 is phosphorylated (Fig. 2A).

Activation of the Kir6.1/SUR2B Channel by Protein Kinase A—In our previous studies (5, 17), we found that β-adrenergic receptor agonists and vasoactive intestinal polypeptide activated vascular KATP channels in the rat mesenteric artery, a response that could be reproduced in recombinant Kir6.1/SUR2B channels expressed in HEK293 cells. We thereby chose to use the recombinant Kir6.1/SUR2B in our current study because the expression system allowed us to manipulate the channel protein. Also because PKA is a common signal molecule by which multiple hormonal vasodilators activate the channel, we used forskolin (10 µM) to investigate the PKA effects. Kir6.1 and SUR2B were expressed in HEK293 cells. Forskolin was applied to the cell when the baseline currents were stabilized in 4–6 min. The exposure to forskolin activated K+ currents that were sensitive to both pinacidil and glibenclamide (Fig. 2B; supplemental Fig. S2). After currents were normalized between maximum channel inhibition by 10 µM glibenclamide and maximum activation by 10 µM pinacidil, the baseline currents averaged 6.0 ± 1.9% (n = 10) of the maximum channel activity. Forskolin (10 µM) increased the currents to 38.5 ± 3.0% (n = 10, Fig. 2E).

Elimination of PKA Activation by Mutation at Arg-1462 or Tyr-506—In the SUR2B_core model, a positively charged residue Arg-1462 was located in the close vicinity of Ser-1387. The distance of the charge of Arg-1462 (measured at the center of two Nh atoms) to the Ser-1387 side chain (Og) was ~8 Å (Fig. 2A). Such a distance may allow an electronic attraction when Ser-1387 is phosphorylated. The mutation of Arg-1462 to alanine indeed eliminated the forskolin-induced channel activation (Fig. 2C). Based on our model prediction, a positive charge at this site is important. This prediction was verified by mutating the Arg-1462 to lysine, and the R1462K mutant remained strongly activated by forskolin (68.5 ± 5.8%, n = 5). The Arg-1462 is located in a consensus PKA site (RKSS), although neither Ser-1464 nor Ser-1465 is a functional PKA phosphorylation site (5). Thus, a positively charged residue critical for the PKA-dependent channel activation is identified in the SUR2B_core model, although it is far from Ser-1387 in the primary sequence.

An aromatic residue, Tyr-506, was found on the ICL2 segment, the side chain of which dipped deeply into NBD2 and physically interacted with Ser-1387 (Fig. 2A). When the Tyr-506 was mutated to alanine, the forskolin-induced channel activation was almost completely abolished (Fig. 2D). A phenylalanine residue is found at the corresponding site in SAV1866 and ICL4 of SUR2B (supplemental Fig. S1). Phenylalanine has a similar side chain as tyrosine but lacks a hydroxyl group. Interestingly, when Tyr-506 was mutated to phenylalanine, the channel failed to be activated by forskolin (Fig. 2E), indicating that the hydroxyl group of Tyr-506 residue is required for channel activation.

Formation of the Ser-1387/Arg-1462/Tyr-506 Triad Following PKA Phosphorylation—Our modeling suggests that PKA phosphorylation at Ser-1387 may induce local conformational changes. To understand these changes, we used MD simulations to reveal changes in residues and the peptide backbone. Our SUR2B_core contained many hydrophobic transmembrane segments that would necessitate time-consuming simulations in the lipid bilayer environment. We therefore constructed two additional models consisting of NBDs and the ICL2 helix with and without Ser-1387 phosphorylation. MD simulations were undertaken at 310 K and 1 atm. After 1000 runs, ICL2 still stayed in the NBD2 groove, suggesting a strong interaction between ICL2 and NBD2. The side chain distances among the three critical residues were monitored (Fig. 3, A and B). Without phosphorylation, the average distance between Tyr-506 and Ser-1387 was 3.8 Å, a distance that allows hydrogen bond formation between these two residues. The Tyr-506/Arg-1462 and Ser-1387/Arg-1462 distances were around 6–7 Å (Fig. 3, A and C), suggesting that there is no direct contact between Arg-1462 and the other two residues before Ser-1387 phosphorylation. When the Ser-387 was phosphorylated, distances of all three were less than 4 Å (Fig. 3C), indicating formation of a compact triad (Fig. 3, D and E). The hydroxyl group of Tyr-506 appeared to be critical for stabilization of the triad, which was able to form hydrogen bonds with oxygen atoms of the phosphate group of pSer-1387 and Nh atoms in Arg-1462, consistent with our observation that forskolin failed to activate the Y506F mutant (Fig. 2E).


Figure 3
View larger version (59K):
[in this window]
[in a new window]

  		FIGURE 3.
Interaction of Tyr-506, Ser-1387, and Arg-1462 following phosphorylation. Molecular dynamics simulations were performed on NBDs and ICL2 with a short flanking sequence (residues 500–512). A phosphate group was linked to atom Og of Ser-1387 representing phosphorylation. A, distances between each pair of residues were monitored before phosphorylation. Y-S was measured between Tyr-506-Oh and Ser-1387-Og. Y-R was measured between Tyr-506-Oh and Arg-1462-Nh1 or Nh2 depending on which one atom was closer to Tyr-Oh. S-R was similarly measured. B, triad distances post-phosphorylation. S represented one of the three Op atoms of the phosphate group of phosphorylated Ser-1387. Six distances were measured between pSer-1387 and Arg-1462, and three between Tyr-506 and pSer-1387, with the closest distances shown. C, summary of the distances among the three residues pre- and post-phosphorylation. The last 800 time frames were counted after stabilization with the initial ~200 runs (see A and B). All three distances were shorter in the post-phosphorylated form. Major changes were seen in distances between Ser-1387 and Arg-1462, and Tyr-506 and Arg-1462. D, mode structure of the triad post-phosphorylation. E, close review of the triad shown in D. The numbers in the figure are the distances (in Å) between the residues of interest. They are slightly and insignificantly different from the average distances shown in C.

 
The Movement of ICL2—Following phosphorylation, the Tyr-506 C{alpha} atoms moved by 9.2 Å in the mode structures. The movement led to a horizontal shift of ICL2 from a position close to the center of NBD2 toward the edge of NBD2 along the NBD2 groove. Because the MD data were acquired after removing most TMDs, the restriction of ICL2 by TMDs was not evaluated. Therefore, this ~10 Å movement might be overestimated. However, the direction appeared reasonable. The Arg-1462 was located at the end of the {alpha}6-helix, close to the edge of NBD2, while Ser-1387 was located on the bottom of the NBD2 groove. With the triad formation, ICL2 was pulled toward NBD2 with lateral sliding along the groove. Meanwhile, the {alpha}2-helix in NBD2 made a lateral move and left space for ICL2 (Fig. 4C).

Reshaping of the NBD2 Groove by Phosphorylation—Studying the conformations of NBD2 of pre-versus post-phosphorylation, we found that NBD2 underwent major conformational changes on the interface with ICL2. The groove for ICL2 binding consisted of residues from β5, {alpha}2, {alpha}3, {alpha}6, Q-loop, and C-loop. The Arg-1462 was the last residue of the long {alpha}6-helix, located close to the edge of NBD2. The {alpha}6-helix was expected to be stable because it was buried in the structure. Indeed, C{alpha}s in the corresponding segment in NBD1 did not significantly change their positions (1.8 ± 0.2 Å, Fig. 5D) in comparison to overall movements of C{alpha}s in NBDs (3.4 ± 0.1 Å). However, the phospho-Ser-1387 (pSer-1387) attracted the positively charged Arg-1462, moving the residue by 4.5 Å toward ICL2 (measured at C{alpha}, Fig. 5, C and D). This movement had major effects on the C-terminal-half (tail) of {alpha}6 (residues 1455–1462) but not the N-terminal-half (head) (residues 1448–1454). The average movement of C{alpha}s in the tail was 4.2 ± 0.3 Å, much greater than the head (2.2 ± 0.3 Å). Consequently, the {alpha}6-helix was slightly bent around Phe-1454 and turned toward ICL2 with an angle ~10°. The movement of the {alpha}6-helix appeared to cause the {alpha}3-helix to move toward ICL2 about 4.2 ± 0.7 Å. Similar to the head of the {alpha}6-helix, the Q-loop was quite stable (2.4 ± 0.3 Å). The C{alpha}sinthe β5-sheet moved toward ICL2 with a distance of 3.0 ± 0.4 Å. The β5 movement was greater than the overall movements of β-sheets in NBD2 (2.3 ± 0.2 Å, p = 0.11) and the corresponding segment in NBD1 (2.4 ± 0.2 Å, p = 0.07). The movement of these segments toward ICL2 suggested a stronger interaction between ICL2 and NBD2 following phosphorylation. In the model, we also observed a large movement (6.9 ± 0.3 Å) of the {alpha}2-helix. The {alpha}2-helix appeared flexible in the SUR2B_core model; it moved toward the edge of NBD2 and yielded space for ICL2.


Figure 4
View larger version (63K):
[in this window]
[in a new window]

  		FIGURE 4.
The movement of ICL2 following phosphorylation. All panels represented the mode structures of the MD simulations. A–C, top views of ICL2 and NBD2 in pre-phosphorylation, post-phosphorylation, and overlay, respectively. The pre-phosphorylation structure was shown in the same set of colors as Fig. 1. In the post-phosphorylation structure, NBD2 was colored red and ICL2 was colored cyan. Compared with the mode structure of the pre-phosphorylated form, ICL2 helix moved horizontally away from the center of NBDs by 8.4 ± 0.4 Å (measured at C{alpha}s of residues 500–506) after phosphorylation. Accordingly, the {alpha}2-helix in NBD2 moved to yield space for ICL2. The arrows in C indicate the direction of movements of ICL2 and the {alpha}2-helix.

 
To make sure that these movements were not random events, the MD simulations were repeated twice for a total of three times with different starting velocities. We observed the same triad formation and protein domain movements in every run. Therefore, even though there may be technical limitations in the MD simulations, we were able to conclude that ICL2 interacted with NBD2 rather loosely before phosphorylation, and the interaction of the two domains was strengthened with the Tyr-506/pSer-1387/Arg-1462 triad formation after phosphorylation.

Restriction of the Interdomain Movement by an Introduced Disulfide Bond—Mutations were engineered in the channel to test the hypothesis that interdomain motion plays a critical role in PKA-dependent channel activation. Forming a disulfide bond between the two domains can restrict the motion thus limiting the channel activation if the motion is critical. Examining all residues in the NBD2 groove and ICL2, we found that a cysteine (Cys-1408) on the wall of the NBD2 groove was close to Ala-507 in ICL2 (Fig. 6A). The distance between the C{alpha}sof the two residues was ~8 Å. When the Ala-507 was mutated to cysteine, the channel activation by forskolin was completely eliminated (Fig. 6B). Because the Ala-507 is located next to Tyr-506, the mutation itself instead of the disulfide bond formation could have affected the channel activation. To address this possibility, we included 3 mM reduced glutathione in the pipette solution and found that the Kir6.1/SUR2B_A507C channel activation by forskolin was nicely restored (29.7 ± 3.0%, n = 5, Fig. 6C). To show whether the introduced Cys-507 indeed formed a disulfide bond with Cys-1408, but not with another unidentified cysteine residue, we mutated Cys-1408 to serine, a residue close to cysteine in side chain properties but unable to form disulfide bonds. The mutant channel (Kir6.1/SUR2B_A507C_C1408S) was activated by forskolin to the same extent as the wild-type channel (Fig. 6, D and E). Thus, the formation of an artificial disulfide bond between residues 507 and 1408 locked the channel in the pre-phosphorylation state and disrupted the channel activation by forskolin, supporting the hypothesis that a relative movement between ICL2 and NBD2 is necessary for channel activation by PKA. We also tried to use the disulfide bond to lock the channel in its open state without success.


Figure 5
View larger version (62K):
[in this window]
[in a new window]

  		FIGURE 5.
Conformational changes in NBD2 interface. A–C, side views of the NBD2 interface in mode structures of pre-phosphorylation, post-phosphorylation, and overlay, respectively. The structures were displayed with the same set of colors in Fig. 4. The backbone of the Arg-1462 (in cyan) moved by 4.5 Å toward ICL2, leading to a movement of the {alpha}6-tail (residues 1455–1462). Major position changes were also seen in {alpha}2- and {alpha}3-helices. The arrows in C indicate the direction of movements of {alpha}6, {alpha}3, and {alpha}2. D, analysis of critical segments in the NBD2 groove. Major changes were seen on NBD2-{alpha}6-tail ({alpha}6t), {alpha}3, and {alpha}2, compared with the corresponding segments in NBD1 (by measuring position changes at C{alpha}s. **, p < 0.001; *, p < 0.05). The β5 in NBD2 (3.0 ± 0.4 Å) appeared to change more than the overall β-sheets in NBD2 (2.3 ± 0.2 Å, p = 0.11) and the corresponding segment in NBD1 (2.4 ± 0.2 Å, p = 0.07). The {alpha}2-helices in both NBDs changed by large distances, suggesting they are flexible. The {alpha}2-helix in NBD2 moved laterally, making space for ICL2. In contrast, NBD2-{alpha}6-head ({alpha}6h) and Q-loop did not show significant position changes.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Modeling SUR2B_Core with SAV1866—The regulatory subunits SURs (ABCC8 and ABCC9) of KATP channels belong to the ABC transporter superfamily. Four ABC proteins have been crystallized in full-length with TMDs and NBDs. The NBDs are similar to each other in their overall structures and assemblies. The TMDs however, are quite different. There are 10 TMHs in each TMD in HI1470/1 (35) and BtuCD (34), while there are 6 in each TMD in SAV1866 (36) and ModBC (33). The TMD in ModBC is much shorter than that in SUR2B, and no evident sequence homology can be found between them. In contrast, the TMD topology of SAV1866 is the same as that of SUR2B, suggesting the validity of modeling the SUR2B_core based on the SAV1866 structural template.

In our SUR2B_core model, NBD1 and NBD2 dimerize to form two nucleotide-binding pockets on their interface, consistent with the models of SUR1-NBDs in previous studies (41, 42). A significant development of our model is to include TMDs and to show the interaction between TMDs and NBDs. SUR2B_TMD1 interacts with NBDs via two short segments ICL1 and ICL2. ICL1 interacts with both NBDs at their borders around the first nucleotide-binding region, while ICL2 is inserted deeply into NBD2. Therefore, the TMD1 mainly interacts with the NBD2. Similar cross-interaction is found in TMD2-NBD1. Our disulfide bond experiment and functional analysis indicate that Cys-1408 in NBD2 is located close to Ala-507 in the TMD1. Evidence supporting such a TMD-NBD cross-interaction also comes from a recent biochemical study (43) on human multidrug transporter (ABCB1), a close homologue of SURs.


Figure 6
View larger version (48K):
[in this window]
[in a new window]

  		FIGURE 6.
Blockade of the PKA effects with disulfide bond between ICL2 and NBD2. A, close-up of residues Ala-507 and Cys-1408. The distance between C{alpha}s of the two residues was ~8 Å, allowing the two residues to form a disulfide bond. B, when Ala-507 was mutated to cysteine, the channel activation by forskolin was abolished. C, when 3 mM of reduced glutathione were included in the pipette solution, forskolin activation of the mutant channel was restored. D, when the Cys-1408 was mutated to serine, a similar residue but cannot form a disulfide bond, the channel behaved like a wt channel. E, summary of forskolin effects on wt and mutants.

 
Importance of Defining the TMD-NBD Interaction in SURs—The TMD-NBD interaction in SUR2B is not only important for PKA activation, but may also provide a structural basis to explain SUR-mediated channel gating by other ligands. For instance, it is well known that NBDs are important for Mg2+-nucleotide activation on KATP channels (13, 25, 26, 28). Although KCOs activate KATP channels via binding to segments in TMDs (12), NBDs are also necessary for KCO effects (13, 24, 25), suggesting an allosteric modulation between these two distinct groups of channel activators. It is unclear how signals in NBDs are coupled to TMDs. Indeed, cis-interaction (TMD1 interacts with NBD1, TMD2 with NBD2) has been assumed to occur in SUR1 (31) and SUR2 (24) based on the mis-assembled MSBA structure (44). Therefore, experimental demonstration of the SAV1866-based NBD-TMD cross-interaction in SUR2B contributes significantly to the understanding of the SUR-mediated gating of KATP channels.

Mechanism of Channel Activation by PKA Phosphorylation—The SUR2B_core model improves our understanding of the mechanism underlying PKA activation of vascular KATP channels. Ser-1387 is a critical phosphorylation site for PKA-dependent activation of Kir6.1/SUR2B channel (5). Data from the current study further support its role in channel activation. Phosphorylation of Ser-1387 leads to a change in the NBD2 conformation and strengthens the interaction of NBD2 with ICL2 through the formation of an interacting triad of residues in different protein domains. Every residue of the triad is critical, as shown in our mutational analysis. The interaction of pSer-1387 and Arg-1462 is apparently caused by the electrostatic attraction. The interactions of Tyr-506 with the other two seem to rely on hydrogen bonds. Our simulation study indicates that the triad is stable and may act as a primary force for the changing conformations of NBD2 and IC2 on their interface. ICL2 appears to move toward NBD2 with phosphorylation, while NBD2 is reshaped and moves toward ICL2, especially the {alpha}6-tail and the {alpha}3-helix and probably the β5-sheet as well. Thus the two domains interact with each other more tightly post-phosphorylation, allowing NBDs to couple with TMDs more effectively. Such a strong NBD-TMD coupling is likely to ensure the transfer of mechanical forces and movements necessary for channel gating between these protein domains. Because such a coupling is weakened without Ser-1387 phosphorylation, the mechanical forces and movements produced in NBDs may not be sufficient for channel gating. By enhancing the NBD-TMD interaction, vasodilators seem to be able to use the existing forces to augment the channel activity without producing additional mechanical work. It is noteworthy that the NBD-TMD force transfer depends on elaborate interactions of the triad, as restriction of these domains with a disulfide bond does not lead to channel activation.

Possible Cooperation of PKA and Nucleotide Activators—The SAV1866 is crystallized in ADP-binding forms (PDB: 2hyd), which is represented as a dimer in NBDs. The NBD dimerization has been seen in almost all the ABC proteins including NBDs of SUR1 (41, 42). In our SUR2B_core model, the two NBDs form a heterodimer with two nucleotide-binding pockets on the interface. Such dimerization of NBD1 and NBD2 in SURs suggests a channel conformation in the active state. Nevertheless, the channel activity is rather low (less than 10% of maximal activity by pinacidil according to our observation in previous and current studies), probably because the interaction between TMDs and NBDs is quite loose at the baseline. PKA phosphorylation enhances the interaction of TMD1 (via ICL2) with NBD2 and thus drastically activates the channel. It is possible that the NBD dimerization by nucleotide binding is necessary for PKA activation. A study (45) on the Kir6.2/SUR1 channel indeed indicates that ADP concentrations determine whether the channel is activated or inhibited by PKA. Although we have not observed inhibition on Kir6.1/SUR2B, we did see a reduction in the PKA effects with decreasing ADP concentrations.5 It is of interest to know whether PKA acts on the channel without nucleotides.

In conclusion, the SAV1866-based modeling provides novel information of SUR2B structures, and suggests a mechanism for the Kir6.1/SUR2B channel activation by PKA phosphorylation, information that is necessary for the understanding of how vasodilators activate KATP channels and relax vascular tension. The discovery of the Ser-1387/Tyr-506/Arg-1462 triad and its critical location for the interaction between TMDs and NBDs contribute significantly to our understanding of SUR-mediated KATP channel gating. Furthermore, our combined studies of SUR2B_core model with mutational analysis support the accuracy of the SAV1866 crystal structure on the NBD-TMD interface and indicate that the SUR2B can be well represented by the SAV1866 structure.


   FOOTNOTES
 
* This work was supported in part by National Institutes of Health Grant HL067890 (to C. J.) and the Georgia State University Research Program Enhancement Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2. Back

1 These authors contributed equally to this work. Back

2 To whom correspondence may be addressed. Tel.: 404-413-5404; Fax: 404-413-5301; E-mail: cjiang{at}gsu.edu. 3 To whom correspondence may be addressed. Tel.: 404-413-5724; Fax: 404-413-5717; E-mail: rharrison{at}cs.gsu.edu.

4 The abbreviations used are: KATP, ATP-sensitive K+ channel; PKA, cAMP-dependent kinase; MD, molecular dynamics; wt, wild type; NBD, nucleotide-binding domain; TMD, transmembrane domain; ICL, intracellular linkers. Back

5 Y. Shi, Z. Wu, and C. Jiang, unpublished data. Back


   ACKNOWLEDGMENTS
 
We thank Dr. S. Seino and Y. Kurachi for gifts of the Kir6.1 and SUR2B cDNAs, respectively. We thank Dr. I. Weber for critical reading of the manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Quayle, J. M., Nelson, M. T., and Standen, N. B. (1997) Physiol. Rev. 77, 1165–1232[Abstract/Free Full Text]
  2. Seino, S., and Miki, T. (2003) Prog. Biophys. Mol. Biol. 81, 133–176[CrossRef][Medline] [Order article via Infotrieve]
  3. Jackson, W. F. (2005) Microcirculation 12, 113–127[Medline] [Order article via Infotrieve]
  4. Quinn, K. V., Giblin, J. P., and Tinker, A. (2004) Circ. Res. 94, 1359–1366[Abstract/Free Full Text]
  5. Shi, Y., Wu, Z., Cui, N., Shi, W., Yang, Y., Zhang, X., Rojas, A., Ha, B. T., and Jiang, C. (2007) Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R1205–R1214[Abstract/Free Full Text]
  6. Nelson, M. T., and Quayle, J. M. (1995) Am. J. Physiol. 268, C799–C822[Medline] [Order article via Infotrieve]
  7. Shyng, S., and Nichols, C. G. (1997) J. Gen. Physiol. 110, 655–664[Abstract/Free Full Text]
  8. Yamada, M., Isomoto, S., Matsumoto, S., Kondo, C., Shindo, T., Horio, Y., and Kurachi, Y. (1997) J. Physiol. 499, 715–720[Abstract/Free Full Text]
  9. Li, L., Wu, J., and Jiang, C. (2003) J. Membr. Biol. 196, 61–69[CrossRef][Medline] [Order article via Infotrieve]
  10. Cui, Y., Tran, S., Tinker, A., and Clapp, L. H. (2002) Am. J. Respir. Cell Mol. Biol. 26, 135–143[Abstract/Free Full Text]
  11. Cole, W. C., and Clement-Chomienne, O. (2003) J. Cardiovasc. Electrophysiol. 14, 94–103[CrossRef][Medline] [Order article via Infotrieve]
  12. Moreau, C., Prost, A.-L., Derand, R., and Vivaudou, M. (2005) J. Mol. Cell Cardiol. 38, 951–963[CrossRef][Medline] [Order article via Infotrieve]
  13. Gribble, F. M., Tucker, S. J., and Ashcroft, F. M. (1997) EMBO J. 16, 1145–1152[CrossRef][Medline] [Order article via Infotrieve]
  14. Wang, X., Wu, J., Li, L., Chen, F., Wang, R., and Jiang, C. (2003) Circ. Res. 92, 1225–1232[Abstract/Free Full Text]
  15. Wellman, G. C., Quayle, J. M., and Standen, N. B. (1998) J. Physiol. 507, 117–129[Abstract/Free Full Text]
  16. Lu, T., Hoshi, T., Weintraub, N. L., Spector, A. A., and Lee, H. C. (2001) J. Physiol. 537, 811–827[Abstract/Free Full Text]
  17. Yang, Y., Shi, Y., Guo, S., Zhang, S., Cui, N., Shi, W., Zhu, D., and Jiang, C. (2008) Biochem. Biophys. Act. 1778, 88–96[CrossRef]
  18. Matsuo, M., Kimura, Y., and Ueda, K. (2005) J Mol. Cell Cardiol. 38, 907–916[CrossRef][Medline] [Order article via Infotrieve]
  19. Higgins, C. F. (1992) Annu. Rev. Cell Biol. 8, 67–113[CrossRef][Medline] [Order article via Infotrieve]
  20. Gaudet, R., and Wiley, D. C. (2001) EMBO J. 20, 4964–4972[CrossRef][Medline] [Order article via Infotrieve]
  21. Smith, P. C., Karpowich, N., Millen, L., Moody, J. E., Rosen, J., Thomas, P. J., and Hunt, J. F. (2002) Mol. Cell 10, 139–149[CrossRef][Medline] [Order article via Infotrieve]
  22. Verdon, G., Albers, S. V., Dijkstra, B. W., Driessen, A. J., and Thunnissen, A. M. (2003) J. Mol. Biol. 330, 343–358[CrossRef][Medline] [Order article via Infotrieve]
  23. Zaitseva, J., Jenewein, S., Jumpertz, T., Holland, I. B., and Schmitt, L. (2005) EMBO J. 24, 1901–1910[CrossRef][Medline] [Order article via Infotrieve]
  24. Yamada, M., and Kurachi, Y. (2004) Mol. Pharmacol. 65, 1198–1207[Abstract/Free Full Text]
  25. Shyng, S., Ferrigni, T., and Nichols, C. G. (1997) J. Gen. Physiol. 110, 643–654[Abstract/Free Full Text]
  26. Yamada, M., Ishii, M., Hibino, H., and Kurachi, Y. (2004) Mol. Pharmacol. 66, 807–816[Abstract/Free Full Text]
  27. Huopio, H., Reimann, F., Ashfield, R., Komulainen, J., Lenko, H. L., Rahier, J., Vauhkonen, I., Kere, J., Laakso, M., Ashcroft, F., and Otonkoski, T. (2000) J. Clin. Investig. 106, 897–906[Medline] [Order article via Infotrieve]
  28. Matsuo, M., Dabrowski, M., Ueda, K., and Ashcroft, F. M. (2002) EMBO J. 21, 4250–4258[CrossRef][Medline] [Order article via Infotrieve]
  29. Schwappach, B., Zerangue, N., Jan, Y. N., and Jan, L. Y. (2000) Neuron 26, 155–167[CrossRef][Medline] [Order article via Infotrieve]
  30. Mikhailov, M. V., Campbell, J. D., de Wet, H., Shimomura, K., Zadek, B., Collins, R. F., Sansom, M. S. P., Ford, R. C., and Ashcroft, F. M. (2005) EMBO J. 24, 4166–4175[CrossRef][Medline] [Order article via Infotrieve]
  31. Babenko, A. P., and Bryan, J. (2003) J. Biol. Chem. 278, 41577–41580[Abstract/Free Full Text]
  32. Chan, K. W., Zhang, H., and Logothetis, D. E. (2003) EMBO J. 22, 3833–3843[CrossRef][Medline] [Order article via Infotrieve]
  33. Hollenstein, K., Frei, D. C., and Locher, K. P. (2007) Nature 446, 213–216[CrossRef][Medline] [Order article via Infotrieve]
  34. Locher, K. P., Lee, A. T., and Rees, D. C. (2002) Science 296, 1091–1098[Abstract/Free Full Text]
  35. Pinkett, H. W., Lee, A. T., Lum, P., Locher, K. P., and Rees, D. C. (2007) Science 315, 373–377[Abstract/Free Full Text]
  36. Dawson, R. J., and Locher, K. P. (2006) Nature 443, 180–185[CrossRef][Medline] [Order article via Infotrieve]
  37. Chen, X., Weber, I. T., and Harrison, R. W. (2004) J. Mol. Model. 10, 373–381[CrossRef][Medline] [Order article via Infotrieve]
  38. Harrison, R. W. (2003) in Proceedings of the International Conference on Computer Science and Its Applications (Gatton, T. M., Dey, P. P., and Amin, M. N., eds) pp. 71–81, U.S. Education Service LLC, San Diego, CA
  39. Harrison, R. W., and Weber, I. T. (1994) Protein Eng. 7, 1353–1363[Abstract/Free Full Text]
  40. Bienengraeber, M., Alekseev, A. E., Abraham, M. R., Carrasco, A. J., Moreau, C., Vivaudou, M., Dzeja, P. P., and Terzic, A. (2000) FASEB J. 14, 1943–1952[Abstract/Free Full Text]
  41. Campbell, J. D., Proks, P., Lippiat, J. D., Sansom, M. S. P., and Ashcroft, F. M. (2004) Diabetes 53, Suppl. 3, S123–S127[Abstract/Free Full Text]
  42. Campbell, J. D., Sansom, M. S. P., and Ashcroft, F. M. (2003) EMBO Rep. 4, 1038–1042[CrossRef][Medline] [Order article via Infotrieve]
  43. Zolnerciks, J. K., Wooding, C., and Linton, K. J. (2007) FASEB J. 21, 3937–3948[Abstract/Free Full Text]
  44. Chang, G. (2003) J. Mol. Biol. 330, 419–430[CrossRef][Medline] [Order article via Infotrieve]
  45. Light, P. E., Manning Fox, J. E., Riedel, M. J., and Wheeler, M. B. (2002) Mol. Endocrinol. 16, 2135–2144[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
R. Masia and C. G. Nichols
Functional Clustering of Mutations in the Dimer Interface of the Nucleotide Binding Folds of the Sulfonylurea Receptor
J. Biol. Chem., October 31, 2008; 283(44): 30322 - 30329.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/12/7523    most recent
M709941200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, Y.
Right arrow Articles by Harrison, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, Y.
Right arrow Articles by Harrison, R. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement